Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Physiologically-Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter-Mediated Interactions Between Metformin and Cimetidine.

Nishiyama K, Toshimoto K, Lee W, Ishiguro N, Bister B, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):396-406. doi: 10.1002/psp4.12398. Epub 2019 Mar 19.

2.

Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake.

Fujino R, Hashizume K, Aoyama S, Maeda K, Ito K, Toshimoto K, Lee W, Ninomiya SI, Sugiyama Y.

Eur J Pharm Sci. 2018 Dec 1;125:181-192. doi: 10.1016/j.ejps.2018.09.021. Epub 2018 Oct 1.

PMID:
30287410
3.

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.

Yoshikado T, Toshimoto K, Maeda K, Kusuhara H, Kimoto E, Rodrigues AD, Chiba K, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):739-747. doi: 10.1002/psp4.12348. Epub 2018 Sep 30.

4.

In Silico Prediction of Major Clearance Pathways of Drugs among 9 Routes with Two-Step Support Vector Machines.

Wakayama N, Toshimoto K, Maeda K, Hotta S, Ishida T, Akiyama Y, Sugiyama Y.

Pharm Res. 2018 Aug 24;35(10):197. doi: 10.1007/s11095-018-2479-1.

PMID:
30143865
5.

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype-Guided Dosing of Tamoxifen.

Nakamura T, Toshimoto K, Lee W, Imamura CK, Tanigawara Y, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul;7(7):474-482. doi: 10.1002/psp4.12307. Epub 2018 Jun 19.

6.

Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.

Yao Y, Toshimoto K, Kim SJ, Yoshikado T, Sugiyama Y.

Drug Metab Dispos. 2018 Jul;46(7):924-933. doi: 10.1124/dmd.117.079210. Epub 2018 Apr 30.

PMID:
29712725
7.

A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography.

Kaneko K, Tanaka M, Ishii A, Katayama Y, Nakaoka T, Irie S, Kawahata H, Yamanaga T, Wada Y, Miyake T, Toshimoto K, Maeda K, Cui Y, Enomoto M, Kawamura E, Kawada N, Kawabe J, Shiomi S, Kusuhara H, Sugiyama Y, Watanabe Y.

Drug Metab Dispos. 2018 May;46(5):719-728. doi: 10.1124/dmd.118.080408. Epub 2018 Mar 19.

PMID:
29555827
8.

Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics.

Sato M, Toshimoto K, Tomaru A, Yoshikado T, Tanaka Y, Hisaka A, Lee W, Sugiyama Y.

Drug Metab Dispos. 2018 May;46(5):740-748. doi: 10.1124/dmd.117.078972. Epub 2018 Feb 23.

PMID:
29475833
9.

Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin.

Futatsugi A, Toshimoto K, Yoshikado T, Sugiyama Y, Kato Y.

Drug Metab Dispos. 2018 May;46(5):749-757. doi: 10.1124/dmd.117.078816. Epub 2018 Feb 12.

PMID:
29440178
10.

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.

Asaumi R, Toshimoto K, Tobe Y, Hashizume K, Nunoya KI, Imawaka H, Lee W, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):186-196. doi: 10.1002/psp4.12275. Epub 2018 Feb 5.

12.

Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.

Kim SJ, Toshimoto K, Yao Y, Yoshikado T, Sugiyama Y.

J Pharm Sci. 2017 Sep;106(9):2715-2726. doi: 10.1016/j.xphs.2017.04.063. Epub 2017 May 4.

PMID:
28479356
13.

Is Ethnic Variability in the Exposure to Rosuvastatin Explained Only by Genetic Polymorphisms in OATP1B1 and BCRP or Should the Contribution of Intrinsic Ethnic Differences in OATP1B1 Be Considered?

Sugiyama Y, Maeda K, Toshimoto K.

J Pharm Sci. 2017 Sep;106(9):2227-2230. doi: 10.1016/j.xphs.2017.04.074. Epub 2017 May 4. No abstract available.

PMID:
28479351
14.

Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins.

Yoshikado T, Toshimoto K, Nakada T, Ikejiri K, Kusuhara H, Maeda K, Sugiyama Y.

Drug Metab Dispos. 2017 Jul;45(7):779-789. doi: 10.1124/dmd.116.074823. Epub 2017 May 3.

PMID:
28468836
15.

Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism.

Fukuchi Y, Toshimoto K, Mori T, Kakimoto K, Tobe Y, Sawada T, Asaumi R, Iwata T, Hashimoto Y, Nunoya KI, Imawaka H, Miyauchi S, Sugiyam Y.

J Pharm Sci. 2017 Sep;106(9):2704-2714. doi: 10.1016/j.xphs.2017.04.052. Epub 2017 Apr 30.

PMID:
28465151
17.

Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure.

Ose A, Toshimoto K, Ikeda K, Maeda K, Yoshida S, Yamashita F, Hashida M, Ishida T, Akiyama Y, Sugiyama Y.

J Pharm Sci. 2016 Jul;105(7):2222-30. doi: 10.1016/j.xphs.2016.04.023. Epub 2016 Jun 1.

PMID:
27262201
18.

Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.

Yoshikado T, Yoshida K, Kotani N, Nakada T, Asaumi R, Toshimoto K, Maeda K, Kusuhara H, Sugiyama Y.

Clin Pharmacol Ther. 2016 Nov;100(5):513-523. doi: 10.1002/cpt.391. Epub 2016 Jul 28.

PMID:
27170342
19.

In silico prediction of major drug clearance pathways by support vector machines with feature-selected descriptors.

Toshimoto K, Wakayama N, Kusama M, Maeda K, Sugiyama Y, Akiyama Y.

Drug Metab Dispos. 2014 Nov;42(11):1811-9. doi: 10.1124/dmd.114.057893. Epub 2014 Aug 14.

PMID:
25128502
20.

Efficient de novo assembly of highly heterozygous genomes from whole-genome shotgun short reads.

Kajitani R, Toshimoto K, Noguchi H, Toyoda A, Ogura Y, Okuno M, Yabana M, Harada M, Nagayasu E, Maruyama H, Kohara Y, Fujiyama A, Hayashi T, Itoh T.

Genome Res. 2014 Aug;24(8):1384-95. doi: 10.1101/gr.170720.113. Epub 2014 Apr 22.

21.

In silico classification of major clearance pathways of drugs with their physiochemical parameters.

Kusama M, Toshimoto K, Maeda K, Hirai Y, Imai S, Chiba K, Akiyama Y, Sugiyama Y.

Drug Metab Dispos. 2010 Aug;38(8):1362-70. doi: 10.1124/dmd.110.032789. Epub 2010 Apr 27.

PMID:
20423955

Supplemental Content

Loading ...
Support Center